Supplemental Disclosure for Statements of Cash Flows (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Cash paid during the period for interest		$ 3,300,000	$ 2,100,000
End-of-term fee		1,000,000	$ 2,400,000
Derivative liabilities		63,000		$ 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock		$ 46,000
Convertible Preferred Stock
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock	$ 46,000
Macrophage Therapeutics \| Convertible Preferred Stock
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock	$ 46,000